Chemo-Free First-Line Treatment Yields Huge PFS Gain in dMMR Endometrial Cancer
(MedPage Today) -- Single-agent immunotherapy as first-line treatment led to a huge improvement in progression-free survival (PFS) in inoperable recurrent/advanced mismatch repair-deficient (dMMR) endometrial cancer, a large randomized trial showed...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.